Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

134.23 +0.27 (+0.20%)
Streaming Delayed Price Updated: 11:54 AM EDT, Jul 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 294,905
Open 133.95
Bid (Size) 134.22 (300)
Ask (Size) 134.24 (200)
Prev. Close 133.96
Today's Range 133.88 - 134.31
52wk Range 34.34 - 134.14
Shares Outstanding 56,367,802
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Halper Sadeh LLC is Investigating Whether NEE, CRBG, RMAX, APGE are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
What This Apogee Insider Move Might Mean After a 247% Stock Run ↗
Henderson's disposition included a 20,000-share open-market sale and a 75,046-share charitable gift. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+77.1%
+77.1%
1 Month
+55.7%
+55.7%
3 Month
+51.7%
+51.7%
6 Month
+69.9%
+69.9%
1 Year
+245.2%
+245.2%

More News

Read More
News headline image
AbbVie Is Already a Dividend King. Here's Why the $10.9 Billion Apogee Deal Could Make It a Dynasty ↗
Via The Motley Fool
Topics Intellectual Property
Apogee Therapeutics (NASDAQ:APGE) Beats Q1 Estimates with Strong Cash Runway and Promising Clinical Progress ↗
Via Chartmill
News headline image
The Dividend ETF Quietly Outperforming the S&P 500 ↗
Via The Motley Fool
Topics ETFs Stocks
News headline image
Shareholder Alert: Ademi LLP investigates whether Apogee Therapeutics is obtaining a Fair Price for Public Shareholders
From Ademi LLP
Via GlobeNewswire
News headline image
This Pharmaceutical Giant Just Poured $11 Billion on an Acquisition. Time to Buy? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Apogee Therapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Apogee Therapeutics, Inc. - APGE
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Halper Sadeh LLC is Investigating Whether APGE, LPRO, HUN, AVNS are Obtaining Fair Deals for their Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
Why AbbVie Stock Jumped Today ↗
Via The Motley Fool
News headline image
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King? ↗
Via The Motley Fool
News headline image
Stock Market Today, June 22: Apogee Therapeutics Soars on AbbVie Cash Buyout Offer ↗
Via The Motley Fool
Topics Stocks
Top movers analysis one hour before the close of the markets on 2026-06-22: top gainers and losers in today's session. ↗
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Apogee Therapeutics, Inc. (Nasdaq – APGE), Simulations Plus, Inc. (Nasdaq – SLP), Roku, Inc. (Nasdaq – ROKU), TruBridge, Inc. (Nasdaq – TBRG)
From Brodsky & Smith LLC
Via GlobeNewswire
Which stocks are moving on Monday? ↗
Via Chartmill
Monday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
APGE Stock Alert: Halper Sadeh LLC is Investigating Whether Apogee Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders
From Halper Sadeh LLC
Via Business Wire
These stocks that are showing activity before the opening bell on Monday. ↗
Via Chartmill
News headline image
Apogee Therapeutics Maps Phase 3 Push for Zumilokibart, Backed by Blackstone Funding ↗
Via MarketBeat
Topics Initial Public Offering
News headline image
Apogee Therapeutics Readies Zumi for Phase 3 With Blackstone Backing ↗
Via MarketBeat
Topics Initial Public Offering
News headline image
Apogee Therapeutics to Participate in Upcoming June Conferences
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis
From Apogee Therapeutics
Via GlobeNewswire
News headline image
Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026
From Apogee Therapeutics
Via GlobeNewswire

Frequently Asked Questions

Is Apogee Therapeutics, Inc. - Common Stock publicly traded?
Yes, Apogee Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Apogee Therapeutics, Inc. - Common Stock trade on?
Apogee Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Apogee Therapeutics, Inc. - Common Stock?
The ticker symbol for Apogee Therapeutics, Inc. - Common Stock is APGE on the Nasdaq Stock Market
What is the current price of Apogee Therapeutics, Inc. - Common Stock?
The current price of Apogee Therapeutics, Inc. - Common Stock is 134.23
When was Apogee Therapeutics, Inc. - Common Stock last traded?
The last trade of Apogee Therapeutics, Inc. - Common Stock was at 07/15/26 11:54 AM ET
What is the market capitalization of Apogee Therapeutics, Inc. - Common Stock?
The market capitalization of Apogee Therapeutics, Inc. - Common Stock is 7.57B
How many shares of Apogee Therapeutics, Inc. - Common Stock are outstanding?
Apogee Therapeutics, Inc. - Common Stock has 8B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.